Agenda
Friday, November 10, 2017
7:00 AM – 8:00 AM | Registration – Arizona II & III Foyer Industry Breakfast Symposium – Arizona II & III |
PROST8™ FOR PRIMARY CARE – Moderator – David Crawford, MD
8:00 – 8:10 AM | Welcome and Introduction E. David Crawford, MD |
8:10 – 8:30 AM | Prostate Physiology: The Most Diseased Organ in the Male Body View Presentation Ryan P. Terlecki, MD, FACS |
8:30 – 8:50 AM | How to Differentiate the Causes of Lower Urinary Tract Symptoms View Presentation Matt T. Rosenberg, MD |
8:50 – 9:10 AM | Association of BPH with OAB View Presentation Ryan P. Terlecki, MD, FACS |
9:10 – 9:30 AM | Prostate Cancer: Why The Controversy? View Presentation Michael S Cookson, MD, MMHC |
9:30 – 9:50 AM | Break and Visit Exhibits – Maricopa II & III |
9:50 – 10:10 AM | Biomarkers: A Way Forward with Prostate Cancer Early Detection View Presentation E. David Crawford, MD |
10:10 – 10:30 AM | Prostate Cancer: Identifying the Toothless Lions View Presentation E. David Crawford, MD |
10:30 – 10:50 AM | Testosterone, the FDA, and CVD Risk Controversies View Presentation Matt T. Rosenberg, MD |
10:50 – 11:10 AM | The Role of Shared Decision-making in Prostate Care View Presentation Matt T. Rosenberg, MD |
11:10 – 11:45 AM | Panel Discussion |
12:00 – 1:00 PM | Industry Lunch Symposium – Maricopa I Elevate Care in Advanced Prostate Cancer Jonathan L. Silberstein, MD Supported by Astellas Pharma US and Pfizer Oncology |
26th PERSPECTIVES IN UROLOGY: POINT COUNTERPOINT
SESSION I: GENERAL UROLOGY – Manoj Monga, MD – Moderator
1:10 – 1:30 PM | ED and the Detection of Subclinical CVD View Presentation Ryan P. Terlecki, MD, FACS |
1:30 – 1:50 PM | Testosterone Therapy Update TBD |
1:50 – 2:10 PM | PCNL: Tips and Tricks View Presentation Manoj Monga, MD |
2:10– 2:40 PM | Point-Counterpoint: TRT Is Safe and Effective Pro: E. David Crawford, MD Testosterone and the Prostate View PresentationCon: Ryan P. Terlecki, MD, FACS Testosterone Safe and Effective? You Better Think Twice View Presentation |
2:40– 3:00 PM | Sexual and Urinary Health After Treatment for Prostate Cancer View Presentation Ryan P. Terlecki, MD, FACS |
3:00 – 3:20 PM | Dietary and Medical Approaches to Kidney Stone Prevention View Presentation Manoj Monga, MD |
3:20 – 3:45 PM | Panel Discussion |
3:45 – 4:00 PM | Break and Visit Exhibits – Maricopa II & III |
SESSION II: BLADDER CANCER – Michael S Cookson, MD, MMHC – Moderator
4:00 – 4:20 PM | BCG Failure: Defining and Managing Difficult Patients View Presentation Michael S. Cookson, MD, MMHC |
4:20 – 4:40 PM | Difficult Issues in Non-Muscle Invasive Bladder Cancer: Guidelines and Beyond View Presentation Michael S. Cookson, MD, MMHC |
4:40 – 5:00 PM | Point Counterpoint: BCG Maintenance – Full SWOG Course
Pro: Erik P. Castle, MD Con:Michael S. Cookson, MD, MMHC |
5:00 – 5:20 PM | Perioperative Management of the Radical Cystectomy Patient. View Presentation Erik P. Castle, MD |
5:20 – 5:40 PM | Immunotherapy for Metastatic Disease View Presentation Alan H. Bryce, MD |
5:40 – 6:00 PM | Muscle Invasive Bladder Cancer: 2017 Guidelines View Presentation Michael S. Cookson, MD, MMHC |
6:00 – 6:30 PM | Point-Counterpoint: The DECIPHER™ Marker Can Predict Chemotherapy Pro: Alan H. Bryce, MD View PresentationCon: Robert Abouassaly, MD View Presentation |
6:30 – 7:30 PM | Welcome Reception in Exhibit Hall – Maricopa II & III Supported by Bayer HealthCare |
Evening | On Own |
Saturday, November 11, 2017
7:00 – 8:00 AM | Industry Breakfast Symposium – Maricopa I Risk Stratification and Molecular Markers E. David Crawford, MD Supported by KOL Consortium LLC |
SESSION III: GENITOURINARY CANCERS
E. David Crawford, MD – Moderator
8:00 – 8:30 AM | Germline and Somatic DNA Repair Defects in Prostate Cancer View Presentation Alan H. Bryce, MD |
8:30 – 9:00 AM | Therapeutic Use of Genetic Testing in Advanced Prostate Cancer View Presentation Alan H. Bryce |
9:00 – 9:30 AM | Recent Advances for Renal Cell Carcinoma View Presentation Erik P. Castle, MD |
9:30 – 10:00 AM | Point-Counterpoint: Genetic Testing Should Be Very Selectively Used in Men Pro: TBD Con: Alan H. Bryce, MD |
10:00 – 10:20 AM | Break and Visit Exhibits – Maricopa II & III |
10:20 – 10:50 AM | Upper Track Cancers View Presentation Robert Abouassaly, MD |
10:50– 11:10 AM | Adjuvant Sunitinib for High Risk RCC View Presentation Alan H. Bryce, MD |
11:00 – 11:30 AM | Cancer Survivorship View Presentation Ryan P. Terlecki, MD, FACS |
11:00 – 12:15 PM | GU Tumor Board Case Panel Moderated by Robert E. Donohue, MD |
12:15 PM – 1:30 PM | Resident’s Bowl Moderated by Erik P. Castle, MD |
Afternoon and Evening | On Own |
Sunday, November 12, 2017
7:00 – 8:00 AM | Industry Breakfast Symposium – Maricopa II & III |
SESSION IV: LOCALIZED PROSTATE CANCER –
Andrew J. Stephenson, MD, FACS, FRCSC – Moderator
8:00 – 8:20 AM | Updates in Radiation Oncology: Of Brachytherapy and Beams? View Presentation David C. Beyer, MD |
8:20 – 8:40 AM | MRI-Guided Biopsies View Presentation Robert Abouassaly, MD |
8:40 – 9:00 AM | MRI in the Management of Prostate Cancer: What the Urologist Needs to Know View Presentation Michael S. Cookson, MD, MMHC |
9:00 – 9:30 AM | Panel Discussion |
9:30 – 9:50 AM | Break and Visit Exhibits – Maricopa II & III |
9:50 – 10:20 AM | Point-Counterpoint: HiFU: Ready for Prime Time?
Pro: David C. Beyer, MD
|
10:20 – 10:40 AM | Imaging of Prostate Cancer Patients Following Definitive Therapy View Presentation Phillip J. Koo, MD |
10:40 – 11:00 AM | Bladder Neck Contractures After Prostatectomy View Presentation Ryan P. Terlecki, MD, FACS |
11:00 – 11:30 AM | Panel Discussion |
11:30 – 12:30 PM | Lunch Break |
SESSION V: ADVANCED PROSTATE CANCER – E. David Crawford, MD – Moderator
12:30 – 12:50 PM | Castrate Resistant Prostate Cancer: Update on Therapy and Sequencing Michael S. Cookson, MD, MMHC |
12:50 – 1:10 PM | Novel Hormonal Therapies for Prostate Cancer View Presentation Alan H. Bryce, MD |
1:10 – 1:30 PM | Therapeutic Radiopharmaceuticals and the Emergence of Theranostics View Presentation Phillip J. Koo, MD |
1:30 – 1:50 PM | Immunotherapy for CRPC View Presentation E. David Crawford, MD |
1:50 – 2:10 PM | Timing and Optimization of Radium 223 in CRPC View Presentation Phillip J. Koo, MD |
2:10 – 3:00 PM | Panel Discussion |
3:00 PM | Closing Remarks E. David Crawford, MD |
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
He is currently a Professor of Urology at the University of California, San Diego, and emeritus distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians.
In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC.
Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.
Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.